AI Due Diligence Framework for Allied Health Investments

Table of Contents

1. Why AI Due Diligence Matters in Allied Health
2. The Three Layers of AI Due Diligence
3. Technical Architecture & Infrastructure Assessment
4. Data Readiness and Quality Evaluation
5. Regulatory, Compliance, and Governance Risk
6. Vendor and AI Model Dependency Mapping
7. Team Capability and Execution Readiness
8. Value Creation Playbook: Post-Acquisition AI Rollout
9. Exit Positioning and AI-Enabled Growth
10. Practical Framework Template and Next Steps

---

Why AI Due Diligence Matters in Allied Health

Allied health represents a $300+ billion global market spanning physiotherapy, occupational therapy, speech pathology, diagnostic imaging, pathology, and allied mental health services. Unlike traditional healthcare IT due diligence—which has matured around EHR compliance, HIPAA architecture, and clinical workflow—allied health AI investments introduce a new risk layer that most PE firms are still learning to evaluate.

The opportunity is real. Allied health businesses suffer from endemic operational inefficiency: manual scheduling, paper-based clinical notes, fragmented patient data, and high staff turnover. AI-driven solutions addressing these pain points have generated 40–60% productivity gains in early-stage implementations, directly translating to margin expansion and revenue per FTE growth. However, the risks are equally material. Allied health professionals—physiotherapists, occupational therapists, speech pathologists—are regulated practitioners whose clinical judgment cannot be delegated to AI. Misapplied automation, poor data governance, or vendor lock-in can destroy trust, trigger regulatory action, and crater valuation.

This guide provides a practical PE operating partner playbook for evaluating AI readiness, identifying value-creation levers, and positioning allied health portfolio companies for exit with defensible AI-enabled growth. Unlike generic AI due diligence frameworks, this approach is grounded in allied health workflow, regulatory constraints, and the specific benchmarks that matter to institutional buyers.

---

The Three Layers of AI Due Diligence

AI due diligence in allied health operates across three interdependent layers: capability assessment, risk quantification, and value extraction. Most PE teams focus only on the first, missing material risks and leaving value on the table.

Layer 1: Capability Assessment

What AI is the target actually running today? Not the pitch deck version—the real, production systems.

• Existing AI systems: What models are deployed? Are they off-the-shelf (ChatGPT, Copilot, Claude) or proprietary? What data do they ingest? What decisions do they inform or automate?
• Data infrastructure: Where does patient data live? How is it structured? Can it be reliably extracted for model training or inference?
• Team skill: Does the target have ML engineers, data scientists, or just business users prompt-engineering with public APIs?
• Vendor dependencies: Which third-party AI platforms (Salesforce, HubSpot, Microsoft, OpenAI) are in the stack? What happens if those vendors change pricing, terms, or capability?

This layer answers: What is the target capable of, and what gaps exist?

Layer 2: Risk Quantification

What could go wrong, and what does it cost?

• Regulatory exposure: Are deployed models auditable? Can the target explain model decisions to regulators or patients? Does the system meet state/territory-based allied health practitioner standards?
• Data governance: Is patient data properly de-identified? Are access logs maintained? Is there a data breach response plan?
• Clinical safety: If the AI system fails, what is the patient impact? Are there manual override mechanisms? Is there liability coverage?
• Vendor risk: If a key AI vendor raises prices 10x or discontinues service, what is the business impact? Can the target migrate?

This layer answers: What are the material risks, and how much capital do we need to remediate them?

Layer 3: Value Extraction

How do we unlock 20–40% EBITDA uplift post-acquisition?

• Workflow automation: Which clinical or operational workflows can be accelerated with AI? What is the time/cost savings per FTE?
• Revenue expansion: Can AI-driven insights (predictive patient outcomes, treatment recommendations) support higher-value service delivery?
• Consolidation synergies: Across a portfolio of allied health businesses, can we share AI infrastructure, data, or models to reduce per-unit costs?
• Exit positioning: Do institutional buyers (strategic PE, healthcare platforms) value AI-enabled growth enough to pay a premium multiple?

This layer answers: How much value can we create, and what is the execution roadmap?

According to research on allied health professionals’ perceptions of AI in healthcare delivery, adoption success depends heavily on clear clinical benefit, transparent governance, and practitioner buy-in—not just technology capability. This shapes due diligence priorities.

---

Technical Architecture & Infrastructure Assessment

The technical foundation of AI systems in allied health is often fragile. Most targets are running on legacy EHR or practice management platforms with bolted-on AI via APIs. Your job is to assess whether the architecture can scale, whether it is secure, and whether it can be owned (not rented from vendors).

Current State Mapping

Start by documenting the actual tech stack:

• Patient data sources: EHR (which vendor? which version?), practice management system (Physio, Secure Practice, Helix, etc.), imaging systems, pathology systems, patient-reported outcomes (PROs), wearables.
• AI integration points: Where do models sit? Are they embedded in the EHR? Running as microservices? Called via API from a third-party platform?
• Data flow: How does patient data move from source to model to decision point? Are there batch pipelines or real-time streams? What is the latency requirement?
• Infrastructure: On-premise, cloud (AWS, Azure, GCP)? Containerised? Scalable? Who owns the keys?

For allied health targets, the most common pattern is: legacy EHR → practice management platform → third-party AI vendor (via API) → clinician dashboard. This creates three failure points: EHR stability, API dependency, and vendor lock-in.

Security and Compliance Readiness

Allied health data is regulated. In Australia, it falls under the Privacy Act and state-based health records legislation. In the US, it is HIPAA-regulated. Your due diligence must confirm:

• Data residency: Where is patient data stored? Does it meet state/territory/country requirements?
• Encryption: Is data encrypted in transit and at rest? Who manages keys?
• Access controls: Can you audit who accessed which patient records and when? Are access logs retained for 6+ years?
• Audit readiness: Can the target pass a SOC 2 Type II audit? Is there a Vanta instance running?

A practical shortcut: ask the target whether they have completed a SOC 2 or ISO 27001 compliance audit. If not, budget 6–12 weeks and $30–80k for remediation post-acquisition. If they have, request the report and review it with your security lead.

According to OECD due diligence guidance for responsible AI, governance frameworks should address human oversight, transparency, and accountability mechanisms—particularly critical in regulated healthcare settings where clinical decisions cannot be fully automated.

Scalability and Cost Structure

Allied health businesses grow via organic patient volume and acquisitions. Your AI infrastructure must scale with volume without exploding costs.

• API costs: If the target is calling OpenAI, Anthropic, or Hugging Face APIs for every patient note, what is the per-inference cost? At 50 inferences per patient per year, across 10,000 patients, that is 500,000 inferences. At $0.01 per inference, that is $5,000/year. At $0.10, it is $50,000/year. Does the model support caching or batch processing to reduce cost?
• Compute costs: If models run on cloud infrastructure (AWS, Azure), what is the monthly bill? Does it scale linearly with patient volume, or is there a fixed base cost that gets amortised across more patients?
• Data storage: Patient data and model artifacts accumulate. What is the annual storage cost? Is there a data retention and purge policy?

For a 50-clinic allied health roll-up, infrastructure costs should scale from $500/clinic/month at 10 clinics to $200/clinic/month at 50 clinics. If costs are rising with scale, the architecture is broken.

---

Data Readiness and Quality Evaluation

AI models are only as good as the data they train on and the data they infer against. In allied health, data quality is typically poor because clinical documentation is optimised for billing and compliance, not ML.

Data Inventory and Extraction

Create a data inventory:

• Patient demographics: Age, gender, location, insurance status. Is this clean? Are there duplicates (same patient, multiple records)?
• Clinical data: Diagnoses (ICD-10 codes), treatments, outcomes, functional assessments (e.g., Functional Independence Measure for occupational therapy). Are these coded consistently, or are they free text?
• Operational data: Appointment dates, clinician utilisation, no-show rates, revenue per session. Is this in the practice management system? Can it be extracted reliably?
• Outcomes data: Patient-reported outcomes (PROs), clinical outcome measures, return-to-work status, satisfaction scores. Are outcomes tracked systematically, or sporadically?

For most allied health targets, the answer is: clinical data exists but is messy; operational data is clean; outcomes data is incomplete. This shapes what AI is feasible.

Data Quality Assessment

Run a data quality audit:

• Completeness: What percentage of records have a given field populated? If diagnosis is missing in 40% of records, you cannot train a diagnostic model.
• Consistency: Are free-text fields (e.g., diagnosis notes) written in a consistent format? Are ICD-10 codes used correctly? A quick sample: pull 100 records and manually review. If more than 20% have obvious errors, data quality is poor.
• Timeliness: How long after a clinical encounter is data entered? If notes are entered days or weeks later, real-time AI inference is not feasible.
• Uniqueness: Are there duplicate records? In a 10,000-patient database, 5–10% duplicates is common. De-duplication is expensive.

Budget $20–40k for a professional data audit. The outcome is a data quality scorecard that informs which AI use cases are feasible and which require data remediation first.

Historical Data for Model Training

If the target wants to build proprietary models (rather than rely on pre-trained, off-the-shelf models), they need historical training data.

• Volume: How many years of historical data exist? For most supervised learning tasks, you need 1,000–10,000 labelled examples. For a physiotherapy clinic with 50 patients per week, that is 2–4 years of data.
• Labelling: Are outcomes labelled? E.g., did a patient recover (yes/no)? Did they return to work? Did they have a re-injury? If outcomes are not recorded, you cannot train a predictive model.
• Bias: Is the historical data representative? If the clinic historically served older patients, a model trained on that data may perform poorly on younger patients. Document demographic distributions.

For most allied health targets, proprietary model training is not feasible in the first 12–24 months post-acquisition. Focus instead on applying pre-trained models (LLMs for note summarisation, clinical decision support tools from established vendors) and building the data infrastructure to support future proprietary models.

---

Regulatory, Compliance, and Governance Risk

Allied health is regulated. Australia has state-based registration boards for physiotherapists, occupational therapists, and speech pathologists. The US has state licensure. The EU has medical device regulations. AI systems that inform or automate clinical decisions fall under these regulatory frameworks.

Clinical Governance and Accountability

The fundamental question: Who is responsible if the AI system makes a wrong recommendation and a patient is harmed?

In allied health, the answer is: the licensed practitioner. AI can inform clinical decision-making, but the practitioner retains accountability. This shapes governance requirements:

• Transparency: The AI system must be explainable. If a model recommends a particular treatment, the clinician must understand why (which features drove the recommendation). Black-box models are acceptable for administrative tasks (scheduling, billing) but risky for clinical decisions.
• Override mechanisms: Clinicians must be able to override AI recommendations without friction. If the system makes it hard to deviate, clinicians will resent it and stop using it.
• Audit trails: Every AI-informed decision must be logged: which model was used, what inputs were provided, what was recommended, what the clinician decided, and what the outcome was. This supports both safety monitoring and regulatory defence.
• Liability insurance: Does the target’s professional indemnity insurance cover AI-assisted decisions? Many policies do not. Budget for updated coverage or risk transfer.

According to research on barriers and enablers of AI adoption in allied health, implementation success depends on clear clinical benefit, regulatory clarity, and practitioner engagement—not just technical capability.

Regulatory Compliance Framework

Map the target’s regulatory obligations:

• Australia: Allied health practitioners are registered with the National Board (via AHPRA). If the target uses AI in clinical decision-making, is the system compliant with the Board’s standards? Are there state-based privacy laws (Victorian Health Records Act, NSW Privacy Act) that apply?
• US: Allied health practitioners are state-licensed. Some states (California, New York) have AI transparency laws. Does the target comply? Is the AI system a medical device (FDA-regulated)? Most clinical decision support tools are not, but if the system diagnoses or treats, it may be.
• EU: Medical devices are regulated under the Medical Device Regulation (MDR). AI-based clinical decision support is a Class II or III device. Is the target’s system CE-marked? If not, it cannot be sold in the EU.

For targets operating only in Australia, regulatory risk is moderate but growing. For targets with US or EU operations, regulatory risk is material. Budget for regulatory consulting ($10–30k) to clarify obligations and remediation requirements.

Data Privacy and Patient Consent

Patient data is sensitive. Using it for AI model training or inference requires consent.

• Consent mechanism: Does the target have explicit patient consent to use data for AI? Or is consent implied (buried in privacy policy)? Explicit consent is stronger legally and ethically.
• De-identification: If data is used for model training or shared with third parties, is it de-identified? Can a patient be re-identified from the de-identified data? If yes, it is not truly de-identified.
• Third-party sharing: If the target shares data with AI vendors (e.g., for model training), what is the data processing agreement? Does the vendor have the same privacy obligations?

---

Vendor and AI Model Dependency Mapping

Most allied health AI implementations rely on third-party vendors and models. This creates dependency risk: if the vendor changes pricing, discontinues service, or gets acquired, what is the business impact?

Vendor Inventory

Create a vendor map:

• Core AI vendors: OpenAI (ChatGPT, GPT-4), Anthropic (Claude), Google (Gemini, Vertex AI), Microsoft (Copilot, Azure OpenAI). What models is the target using? For what use cases?
• Vertical AI vendors: Clinical decision support platforms (e.g., Nuance, Ambient Intelligence), scheduling optimisation (e.g., Optima Health), revenue cycle management (e.g., Phreesia). What is the contract term? What is the pricing model (per user, per transaction, per patient)?
• Infrastructure vendors: AWS, Azure, GCP. What services are in use (compute, storage, AI services)? What is the monthly bill? Is there a committed spend discount?
• Data and analytics vendors: Tableau, Looker, Superset. Are these used for AI-informed dashboards?

For each vendor, assess:

• Switching cost: If we switched to a competitor, how much would it cost (data migration, re-training, downtime)? If switching costs are high, we are locked in.
• Pricing risk: What is the contract term? When does it renew? What is the historical price increase? If a vendor has raised prices 20% annually, budget for that trend.
• Concentration risk: If 50% of revenue depends on one vendor, that is material risk. Diversify or negotiate a long-term price lock.

Model Ownership and Portability

Who owns the AI models? Can they be moved to a different vendor?

• Off-the-shelf models: If the target uses OpenAI’s GPT-4 or Anthropic’s Claude, the target does not own the model. But the target can switch vendors relatively easily (repoint API calls).
• Fine-tuned models: If the target has fine-tuned a model on proprietary data, does the target own the fine-tuned weights? Or does the vendor own them? Check the terms of service. Most vendors allow ownership of fine-tuned models, but some (older versions of some platforms) do not.
• Proprietary models: If the target has trained a model from scratch on proprietary data, the target owns it. But can it be deployed on alternative infrastructure? If it is trained on vendor-specific tools (e.g., Azure ML), migration is expensive.

For allied health targets, the safest approach is: use off-the-shelf models from multiple vendors, avoid deep vendor lock-in, and invest in proprietary models only for defensible competitive advantages (e.g., outcome prediction models trained on 5+ years of proprietary data).

---

Team Capability and Execution Readiness

AI is only as good as the team running it. Assess the target’s technical and operational capability to manage AI systems post-acquisition.

Technical Team Assessment

Interview the target’s technical leadership:

• CTO/VP Engineering: Do they have AI/ML experience? Have they shipped AI products before? Can they articulate the technical roadmap? If the CTO is a traditional infrastructure engineer with no AI experience, you will need to hire or bring in fractional leadership.
• Data team: Does the target have data engineers, data scientists, or ML engineers? How many? What is their experience level? For allied health, most targets have 0–1 data roles, which is insufficient for serious AI work.
• Infrastructure: Who manages cloud infrastructure? Are they proficient in AWS, Azure, or GCP? Can they set up monitoring, logging, and cost controls?

For most seed-to-Series-B allied health targets, the technical team is weak on AI. Budget for hiring or contracting fractional CTO leadership post-acquisition. Options include:

• Hiring a full-time CTO or VP Engineering ($150–250k salary + equity)
• Engaging a fractional CTO advisor (20–40 hours/month, $8–15k/month) to mentor internal team and advise on architecture
• Partnering with a venture studio or AI agency (like PADISO’s CTO Advisory service in Sydney or fractional CTO services in other markets) for embedded technical leadership and delivery

Product and Operations Readiness

AI projects fail not because of technology but because of unclear requirements, poor prioritisation, and slow execution.

• Product management: Does the target have a product manager or operator who can define AI use cases, prioritise them, and measure impact? If not, AI projects will drift.
• Change management: Are clinicians ready for AI-assisted workflows? Have they been consulted? Will they adopt the system? Resistance to change is the #1 reason AI projects fail in healthcare.
• Metrics and measurement: Can the target measure the impact of AI (time saved, revenue uplift, outcome improvement)? If not, you cannot quantify value creation or decide which AI projects to fund.

Hiring and Retention Risk

Tech talent is scarce and expensive. Allied health businesses are not typically tech-first, so they struggle to attract and retain engineers.

• Compensation: Is the target paying market rates for engineers? Allied health is not fintech or crypto, so equity alone will not attract talent. Budget for competitive salaries.
• Culture: Is there a technical culture? Do engineers have autonomy to make decisions? Are they consulted on product roadmap? If engineering is seen as a cost centre, talent will leave.
• Career development: Can engineers grow? Is there a path to principal engineer, staff engineer? Or is the ceiling low?

Post-acquisition, you will likely need to hire 2–4 engineers to build out AI capability. Budget $300–500k annually (salary + benefits + overhead) for this team.

---

Value Creation Playbook: Post-Acquisition AI Rollout

Once you have acquired an allied health business and assessed its AI readiness, how do you unlock value? Here is a practical playbook.

Phase 1: Audit and Stabilise (Weeks 1–4)

• Technical audit: Map the current tech stack, data flows, and AI systems. Identify fragility, technical debt, and security gaps.
• Data audit: Assess data quality, completeness, and readiness for AI.
• Team assessment: Evaluate technical capability. Identify gaps (missing data engineer, weak CTO, no product manager).
• Compliance audit: Confirm regulatory obligations and remediation requirements.
• Output: A 30-page technical and operational assessment with prioritised remediation roadmap.

Budget: $30–60k (internal team + external consultants).

Phase 2: Quick Wins (Weeks 5–12)

Identify and execute 2–3 low-hanging-fruit AI projects that deliver visible value in 6–8 weeks.

Example 1: Automated Clinical Note Summarisation

Problem: Clinicians spend 20–30% of time on documentation. Opportunity: Use an LLM (GPT-4, Claude) to auto-summarise clinical notes, saving 5–10 hours per clinician per week.

• Approach: Integrate OpenAI API or Azure OpenAI into the EHR or practice management system.
• Data: Anonymised clinical notes (no patient identifiers in the API call).
• Outcome: 5–10 hours/week saved per clinician. For a 50-person clinic, that is 250–500 hours/week = $10–20k/month in recovered time.
• Timeline: 4–6 weeks to build and deploy.
• Cost: $10–20k (engineering effort) + $500–1,000/month (API costs).

Example 2: Predictive No-Show Reduction

Problem: Allied health clinics typically have 15–25% no-show rates, costing 10–15% of revenue. Opportunity: Use historical data to predict which patients will no-show, then intervene (automated SMS reminder, phone call).

• Approach: Build a logistic regression or random forest model on historical appointment and patient data.
• Data: Appointment date, time, clinician, patient demographics, previous no-show history, lead time (days between booking and appointment).
• Outcome: Reduce no-show rate from 20% to 15%, recovering $50–100k/year in revenue for a $2M clinic.
• Timeline: 6–8 weeks to build, test, and deploy.
• Cost: $15–30k (data science effort) + $500–1,000/month (infrastructure).

Example 3: AI-Powered Scheduling Optimisation

Problem: Manual scheduling is inefficient. Clinicians have gaps; patients have long wait times. Opportunity: Use constraint-satisfaction algorithms to optimise clinician schedules, reducing gaps and wait times.

• Approach: Integrate a scheduling optimisation API (e.g., Google OR-Tools) or vendor (e.g., Optima Health) into the practice management system.
• Data: Clinician availability, patient appointment types, duration, preferences, travel time between locations.
• Outcome: Increase clinician utilisation from 75% to 85%, recovering 10% of capacity. For a $2M clinic, that is $200k in incremental revenue.
• Timeline: 8–10 weeks to configure, integrate, and deploy.
• Cost: $20–40k (integration) + $2–5k/month (vendor fees).

Execute 2–3 of these projects in parallel. By week 12, you should have shipped at least one and be seeing measurable value.

Phase 3: Capability Build (Weeks 13–26)

Now that you have momentum, invest in building sustainable AI capability.

• Hire or contract technical leadership: Bring in a fractional CTO or hire a VP Engineering. They will own the AI roadmap and team building.
• Build the data foundation: Invest in data infrastructure (data warehouse, ETL pipelines, data quality monitoring). This is unglamorous but essential for scalable AI.
• Define the AI roadmap: Prioritise 5–10 AI use cases across clinical, operational, and revenue domains. Estimate impact and effort for each.
• Establish governance: Create an AI governance committee (CEO, CTO, Head of Clinical, Head of Operations) that meets monthly to review AI projects, measure impact, and manage risk.

Budget: $100–200k (team + infrastructure + consulting).

Phase 4: Scale and Consolidation (Weeks 27–52)

Roll out AI across the portfolio.

• Horizontal scaling: If you have acquired multiple allied health businesses, can you consolidate AI infrastructure and share models? E.g., a no-show prediction model trained on 10,000 appointments from one clinic can be deployed to another clinic with minimal retraining.
• Vertical deepening: For the most valuable use cases (e.g., outcome prediction, revenue optimisation), invest in proprietary models trained on consolidated portfolio data.
• Vendor consolidation: Rationalise AI vendors. If three clinics are using three different scheduling systems, migrate to one. Reduce per-unit costs.

Budget: $200–400k (engineering + infrastructure).

By the end of year 1, a well-executed AI rollout should deliver:

• 20–30% improvement in clinician productivity (via automation of documentation, scheduling, admin tasks).
• 10–15% reduction in no-show rates (via predictive interventions).
• 5–10% improvement in clinical outcomes (via AI-informed treatment recommendations).
• $500k–$2M in incremental EBITDA across a 5–10 clinic portfolio.

These are conservative benchmarks. Some targets will exceed them; others will fall short. The key is measurement and iteration.

---

Exit Positioning and AI-Enabled Growth

When you exit, how much premium do you get for AI capability? The answer depends on how defensible and material the AI is.

Exit Buyer Profiles

Strategic acquirers (larger healthcare platforms, allied health roll-ups):

• Value AI for consolidation synergies: A larger platform can deploy your AI across 100+ clinics, amortising development costs and improving unit economics.
• Typical multiple: 0.5–1.0x EBITDA premium for proven, scalable AI capability.

PE buyers (secondary PE, growth equity):

• Value AI for growth and margin expansion: AI-enabled productivity gains support higher growth and better margins, justifying a higher multiple.
• Typical multiple: 0.3–0.7x EBITDA premium for credible AI roadmap and early traction.

Institutional buyers (health tech platforms, listed healthcare companies):

• Value AI for defensibility and competitive moat: Proprietary models trained on unique data are defensible.
• Typical multiple: 1.0–2.0x EBITDA premium for proprietary, defensible AI capability.

AI Narrative for Exit

When you pitch to buyers, lead with concrete outcomes, not hype.

Weak narrative: “We use AI to improve operations.”

Strong narrative: “We deployed predictive no-show models across 15 clinics, reducing no-show rates from 22% to 16%, recovering $1.2M in annual revenue. We built a proprietary outcome prediction model trained on 50,000 patient records, enabling clinicians to identify high-risk patients early and improve treatment plans. We consolidated AI infrastructure across the portfolio, reducing per-clinic infrastructure costs from $3,000/month to $1,200/month. This AI capability is defensible (proprietary models and data), scalable (deployed across 15 clinics with >80% utilisation), and material (contributing 20% of EBITDA growth).”

The second narrative is compelling because it is specific, quantified, and defensible.

Preparation for Exit (12 Months Prior)

1. Audit AI systems: Ensure all AI systems are documented, governed, and auditable. Buyers will conduct technical due diligence; weak governance is a red flag.
2. Quantify impact: For each AI system, measure impact (time saved, revenue generated, cost reduced). Provide 12+ months of data.
3. De-risk vendor dependencies: If the business relies on one vendor, negotiate long-term pricing or invest in alternatives.
4. Build the narrative: Create a 10-slide deck on AI capability, roadmap, and impact. Practice the pitch.
5. Hire or contract a fractional CTO: If your internal team is weak, bring in external leadership for the exit process. Buyers want to see credible technical leadership.

For allied health targets, engaging a fractional CTO advisor in the 12 months before exit is a smart investment. They can audit AI systems, advise on positioning, and mentor internal team through technical due diligence.

---

Practical Framework Template and Next Steps

AI Due Diligence Scorecard

Use this scorecard to evaluate targets on a 1–5 scale (1 = major risk, 5 = best-in-class):

Category	Criteria	Score	Notes
Data Readiness	Data completeness and quality
	Historical data volume for training
	Data governance and privacy controls
Technical Architecture	Cloud infrastructure maturity
	Security and compliance readiness
	Scalability and cost structure
AI Capability	Existing AI systems and models
	Vendor dependencies and lock-in risk
	Proprietary IP and defensibility
Team	Technical leadership (CTO/VP Eng)
	Data science and engineering capability
	Product and change management
Regulatory & Governance	Clinical governance framework
	Regulatory compliance (HIPAA, privacy)
	Audit readiness (SOC 2, ISO 27001)
Value Potential	Identified quick-win use cases
	Addressable market for AI solutions
	Consolidation synergies (portfolio)

Scoring guidance:

• Score 4–5: Low risk, high opportunity. Proceed with confidence.
• Score 3: Moderate risk, moderate opportunity. Proceed with remediation plan.
• Score 1–2: High risk. Either pass or budget significant remediation ($100k+).

Post-Acquisition 100-Day Plan

Days 1–14: Audit and Assessment

• Technical audit (tech stack, data, AI systems, security)
• Team assessment (capability, gaps, hiring needs)
• Regulatory and compliance review
• Deliverable: 20-page technical assessment

Days 15–30: Remediation Planning

• Prioritise remediation items (security, compliance, technical debt)
• Define quick-win projects (2–3 AI use cases, 6–8 week timeline)
• Hire or contract fractional CTO if needed
• Deliverable: 100-day execution plan

Days 31–60: Quick Wins Execution

• Execute first quick-win project (e.g., note summarisation)
• Measure impact (time saved, revenue, cost)
• Build team confidence and momentum
• Deliverable: First shipped project with measured impact

Days 61–100: Capability Build

• Hire technical team (data engineer, ML engineer, product manager)
• Build data infrastructure (data warehouse, ETL)
• Define 12-month AI roadmap
• Establish AI governance
• Deliverable: Technical roadmap and team in place

Engagement Options

If your team lacks deep AI and healthcare technical expertise, consider engaging an external partner:

• Fractional CTO advisory: A fractional CTO (20–40 hours/month) can audit technical systems, advise on architecture and hiring, and mentor internal team. Cost: $8–15k/month. Engagement: 6–12 months.
• Platform engineering and AI delivery: For complex projects (data infrastructure, proprietary models), engage a platform engineering team. Cost: $30–80k per project. Timeline: 8–16 weeks.
• AI strategy and readiness: If you are evaluating multiple targets, engage an AI strategy advisor to define due diligence framework and value-creation playbook. Cost: $15–30k. Timeline: 4–6 weeks.

For allied health PE investors in Australia, PADISO’s fractional CTO and AI advisory services in Sydney are tailored to healthcare and PE-backed companies. For US targets, platform engineering services in Boston, San Francisco, and New York provide healthcare-specific architecture and compliance expertise.

---

Summary: The Allied Health AI Investment Thesis

Allied health represents a compelling AI investment opportunity: large market, endemic operational inefficiency, regulatory tailwinds, and clear value-creation levers. However, success requires rigorous due diligence, disciplined execution, and deep technical expertise.

The framework in this guide—three-layer due diligence (capability, risk, value), technical and data assessment, regulatory governance, team evaluation, and post-acquisition value creation—provides a practical playbook for PE investors.

Key takeaways:

1. AI due diligence is material: Weak AI readiness is a red flag. Budget for remediation or pass.
2. Data is foundational: Poor data quality limits AI opportunity. Invest in data audit and remediation early.
3. Quick wins build momentum: Ship 2–3 AI projects in the first 12 weeks to prove value and build team confidence.
4. Technical leadership is critical: Hire or contract a fractional CTO. This is not optional.
5. Governance and compliance matter: Clinical governance, regulatory compliance, and audit readiness are table stakes, not nice-to-haves.
6. Exit positioning is important: Quantify AI impact, de-risk vendor dependencies, and build a compelling narrative for buyers.

Following this playbook, a well-executed allied health AI investment can deliver 20–40% EBITDA uplift and 1.0–2.0x EBITDA exit multiple premium.

The next step: define your AI due diligence framework, hire or contract technical advisors, and begin evaluating targets through this lens. Your portfolio will thank you.

---

Additional Resources and Support

For PE investors seeking to deepen their AI due diligence capability, consider these resources:

• NIST AI Risk Management Framework (AI RMF 1.0) provides a governance framework for managing AI risks, including assessment and monitoring.
• Bain’s perspective on new diligence challenges in AI offers a PE-focused view on evaluating AI impact on business models and competition.
• McKinsey’s analysis of generative AI’s economic potential provides benchmarks for productivity gains and value creation.
• Sirion’s practical guide to AI-assisted due diligence covers workflows and risk detection in deal review.
• World Economic Forum’s AI Governance Alliance offers principles and implementation guidance for AI governance.

For technical execution, allied health PE investors should engage partners with proven healthcare and compliance expertise. PADISO’s case studies showcase real implementations across healthcare, regulated industries, and platform engineering. For fractional CTO leadership across major US markets, PADISO provides advisory services in Boston, New York, San Francisco, and Melbourne, with specialisation in healthcare architecture and regulatory readiness.

For security and compliance, SOC 2 and ISO 27001 audit readiness via Vanta is a practical path to enterprise-grade governance in 6–12 weeks, critical for exit positioning and buyer confidence.